Video

Ursula Matulonis Explains the Use of PARP Inhibitors for Ovarian Cancer

Author(s):

Ursula Matulonis, M.D.
Conference|SGO Annual Meeting on Women's Cancer

Ursula Matulonis, M.D., professor of Medicine, Harvard Medical School, Medical Director of Gynecologic Oncology, Dana-Farber Cancer Institute, explains the benefits of PARP inhibitors for patients with ovarian cancer.

Ursula Matulonis, M.D., professor of Medicine, Harvard Medical School, Medical Director of Gynecologic Oncology, Dana-Farber Cancer Institute, explains the benefits of PARP inhibitors for patients with ovarian cancer.

PARP inhibitors work by blocking the repair of DNA within cancer cells, which then allows other DNA repair molecules to target the broken DNA strand.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
image of gerds
Image of 2 doctors and text.
Image of two doctors and text.
Image of thumbnail.
Image of doctor.
Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.
Image of woman.
Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.
Image of woman.
Image of smiling doctor.
Related Content
Image of two doctors with text.
June 13th 2025

Updates in Shared Decision-Making in Lung Cancer Following ASCO 2025

Ryan Scott
Treating patients with lung cancer always calls for a focus on informed and shared decision-making, according to expert oncologists.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Image of two doctors and text.
June 12th 2025

What Patients With Genitourinary Cancers Need to Know After ASCO 2025

Ryan Scott
Dr. Joshua K. Sabari and Dr. Daniel V. Araujo provide expert insights into genitourinary cancer updates from ASCO 2025.
cancer horizons image for podcast
December 14th 2023

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon Alex Biese
CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.
Image of hand.
June 10th 2025

Oncology Nurse Amanda Snyder Turns Personal Experience Into Advocacy

Jeanine Pronio
Amanda Snyder, a cancer survivor, became an oncology nurse to provide support she once lacked, now leading innovative therapies for patients.
Dr. Mabel Mardones educates patients on breast cancer updates: © stock.adobe.com.
June 10th 2025

Understanding Breast Cancer Biomarkers Drives Patient Treatment Decisions

Kristie L. Kahl
Dr. Mabel Mardones educates patients on breast cancer subtypes, as well as treatment options for those with ER-positive, HER2-negative disease.